Results 11 to 20 of about 14,850 (194)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. [PDF]

PLoS ONE, 2016
Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 ...
Yoon-Kyung Chang, Hyunsu Choi, Jin Young Jeong, Ki-Ryang Na, Kang Wook Lee, Beom Jin Lim, Dae Eun Choi   +6 more
doaj   +1 more source

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

Frontiers in Pharmacology, 2021
As a newly approved oral hypoglycaemic agent, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which is derived from the natural product phlorizin can effectively reduce blood glucose.
Liuran Li, Qinghua Li, Wenbin Huang, Yibing Han, Huiting Tan, Min An, Qianru Xiang, Rui Zhou, Li Yang, Li Yang, Yanzhen Cheng   +10 more
doaj   +1 more source

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

Molecules, 2020
Dapagliflozin, empagliflozin, tofogliflozin, selective inhibitors of sodium-glucose cotransporter 2 (SGLT2), is used clinically to reduce circulation glucose levels in patients with type 2 diabetes mellitus by blocking the reabsorption of glucose by the ...
Junichi Okada, Eijiro Yamada, Tsugumichi Saito, Hideaki Yokoo, Aya Osaki, Yoko Shimoda, Atsushi Ozawa, Yasuyo Nakajima, Jeffrey E. Pessin, Shuichi Okada, Masanobu Yamada   +10 more
doaj   +1 more source

Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished.
Hilmi Alnsasra, Hilmi Alnsasra, Gal Tsaban, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Abed N. Azab, Joseph Azuri, Joseph Azuri, Ariel Hammerman, Ronen Arbel   +12 more
doaj   +1 more source

Targeting Autophagy, Apoptosis, and Oxidative Perturbations with Dapagliflozin Mitigates Cadmium-Induced Cognitive Dysfunction in Rats

Biomedicines, 2023
Cognitive decline and Alzheimer-like neuropathology are common manifestations of cadmium toxicity. Thanks to its antioxidant/anti-apoptotic features, dapagliflozin has demonstrated promising neuroprotective actions. However, its effect on cadmium-induced
Hany H. Arab, Ahmed H. Eid, Shuruq E. Alsufyani, Ahmed M. Ashour, Azza A. K. El-Sheikh, Hany W. Darwish, Fatma M. Sabry   +6 more
doaj   +1 more source

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

BMC Pulmonary Medicine, 2022
Background Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), can reduce cardiovascular events and mortality in patients with heart failure. A number of mechanisms have been proposed to explain the beneficial effects of SGLT2
Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie   +13 more
doaj   +1 more source

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice

Frontiers in Pharmacology, 2022
Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of NAFLD, growing evidence suggests that tight glycemic ...
Panshuang Qiao, Yingli Jia, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou   +9 more
doaj   +1 more source

Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes

Heliyon, 2023
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinically reduce atherosclerosis and lower blood pressure. However, their impact on endothelial dysfunction in type 2 diabetes (T2D) remains unclear.
Shi Tai, Ying Zhou, Liyao Fu, Huiqing Ding, Yuying Zhou, Zhiyi Yin, Rukai Yang, Zhenjiang Liu, Shenghua Zhou   +8 more
doaj   +1 more source

Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism, 2015
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries.
Deborah Hinnen
doaj   +1 more source

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Frontiers in Pharmacology, 2021
Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms.
Dong-Yuan Chang, Dong-Yuan Chang, Dong-Yuan Chang, Xiao-Qian Li, Xiao-Qian Li, Xiao-Qian Li, Min Chen, Min Chen, Min Chen, Ming-Hui Zhao, Ming-Hui Zhao, Ming-Hui Zhao   +11 more
doaj   +1 more source